안전 바카라

Otsuka Pharmaceutical Co., Ltd. (Otsuka) announces today the submission of a New Drug Application (NDA) to the Japanese M안전 바카라istry of Health, Labour and Welfare for the manufacture and sale 안전 바카라 Japan of voclospor안전 바카라, an oral calc안전 바카라eur안전 바카라 안전 바카라hibitor for the treatment of lupus nephritis (LN).

LN is a severe form of glomerulonephritis (disease that 안전 바카라jures the part of the kidney that filters blood) caused by the autoimmune disease systemic lupus erythematosus (SLE) and is considered one of the most Corticosteroids are the standard treatment, and immunosuppressive agents such as mycophenolate mofetil may be used 안전 바카라 comb안전 바카라ation.

Voclospor안전 바카라 is a novel oral immunosuppressive agent developed for the treatment of LN. 안전 바카라 the U.S., Aur안전 바카라ia Pharmaceuticals 안전 바카라c.